Salvage haploidentical or cord-blood allogeneic stem cell transplantation after a prior alternative allograft in hematologic malignancies: a retrospective study from the SFGM-TC.
Fiche publication
Date publication
septembre 2022
Journal
European journal of haematology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERCEANU Ana, Pr RUBIO Marie Thérèse
Tous les auteurs :
Cavalieri D, Rubio MT, Corriger A, Pereira B, Cabrespine A, Robin M, Labussière-Wallet H, Calleja A, Forcade E, Chevallier P, Guillerm G, Berceanu A, Bulabois CE, Maillard N, Nguyen S, Raus N, Schoemans H, Bay JO, Ravinet A
Lien Pubmed
Résumé
Haploidentical (haplo-) donors and cord-blood (CB) stem cells provide alternative transplant options in patients lacking an HLA-matched donor. In case of relapse or graft failure after a first alternative allogeneic hematopoietic stem cell transplant (HSCT), a second alternative HSCT (HSCT2) is rarely considered due to a high risk of toxicity.
Mots clés
Allogeneic Transplantation, Cord Blood Stem Cell Transplantation, Haploidentical Transplantation, Salvage Therapy
Référence
Eur J Haematol. 2022 09 24;: